BioCentury | Jun 3, 2013
Company News

Alethia, International Biotech Center (IBC) Generium deal

...Alethia and IBC Generium partnered to co-develop Alethia's AB-16B5 , an IgG2 mAb against clusterin (CLU...
...the Commonwealth of Independent States (CIS). IBC has the option to license exclusive rights to AB-16B5...
BioCentury | Dec 14, 2009
Clinical News

Alethia preclinical data

...In a mouse model of metastatic cancer, AB-16B5 plus Taxotere docetaxel increased tumor growth inhibition by...
...tumor growth inhibition by 40-60% vs. chemotherapy alone. In a mouse model of breast carcinoma, AB-16B5...
...sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) markets Taxotere. Alethia BioTherapeutics Inc. , Montreal, Quebec Product: AB-16B5...
Items per page:
1 - 2 of 2